NKCC

NKCC Products

All (5)
NKCC Inhibitors (5)
New NKCC Products

Catalog No.	Product Name	Information	Product Use Citations
S8615	DCA (Sodium dichloroacetate)	DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na⁺-K⁺-2Cl^- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.	Cell Mol Life Sci, 2024, 81(1):324 Free Radic Biol Med, 2024, 224:39-49 iScience, 2024, 27(1):108645
S1603	Furosemide	Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.	Ren Fail, 2022, 44(1):1345-1355 Environ Toxicol Chem, 2021, 10.1002/etc.5018 Biomed Pharmacother, 2018, 101:145-154
S1287	Bumetanide	Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.	Cancer Med, 2024, 13(11):e7291 Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j
S5194	Furosemide sodium	Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.	Nat Commun, 2024, 15(1):7342 Ren Fail, 2022, 44(1):1345-1355
E2358	Azosemide	Azosemide is a potent Na⁺–K⁺–2Cl⁻ cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.
S8615	DCA (Sodium dichloroacetate)	DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na⁺-K⁺-2Cl^- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.	Cell Mol Life Sci, 2024, 81(1):324 Free Radic Biol Med, 2024, 224:39-49 iScience, 2024, 27(1):108645
S1603	Furosemide	Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.	Ren Fail, 2022, 44(1):1345-1355 Environ Toxicol Chem, 2021, 10.1002/etc.5018 Biomed Pharmacother, 2018, 101:145-154
S1287	Bumetanide	Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.	Cancer Med, 2024, 13(11):e7291 Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j
S5194	Furosemide sodium	Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.	Nat Commun, 2024, 15(1):7342 Ren Fail, 2022, 44(1):1345-1355
E2358	Azosemide	Azosemide is a potent Na⁺–K⁺–2Cl⁻ cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.

Choose Selective NKCC Inhibitors